This trial is investigating a medication for treating people living with non-segmental vitiligo.
Vitiligo causes white patches on your skin when the cells that provide colour to your skin are destroyed. Non-segmental Vitiligo affects both sides of the body, such as both knees and both hands.
The investigational drug for this study is Ritlecitinib and is given as an oral tablet. Ritlecitinib is a treatment for diseases of a similar nature to vitiligo, and has been well tolerated in previous clinical trials.
The purpose of this research project is to measure how safe and effective this medication is in treating participants with non-segmental vitiligo. Ritlecitinib selectively inhibits the body’s immune response. The outcome of this project could support new treatments to increase quality of life in people with non-segmental vitiligo.
Anticipated enrolment close date: To be determined
Who can take part
This trial might be right for you, if you:
- are at least 18 years of age with diagnosis of non-segmental vitiligo for at least 3 months.
- more than 0.5% of your face show signs of vitiligo
This trial is likely not right for you if you:
- have been diagnosed with other types of vitiligo (for example, segmental or mixed vitiligo)
- have had a significant viral infection history
- experience significant trauma or major surgery within 1 month of the first dose of study drug
- have a history of suicidal ideation
Participants will need to:
- attend the RMH about 10 times over the 12-month trial period. Most study visits should take about one hour, however your first and second visit will be longer.
- undergo a medical history review, hearing tests, physical examination, height and weight
- provide blood and urine samples
All research in Australia involving human participants is reviewed by an independent group called a Human Research Ethics Committee (HREC). The ethical aspects of this research study have been approved by the Royal Melbourne Hospital HREC.
This study is being carried out according to the National Statement on Ethical Conduct in Human Research (2007). This statement protects the interests of people who agree to participate in human research studies.